PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 6442829

Partial inhibitory seizures: a report on two cases.

P J Wang·K Omori·H Utsumi·T Izumi·K Yajima·Y Fukuyama
View original source ↗Export metadata ↓

Abstract

This paper described two epileptic children with the clinical features of tonic-clonic seizures, brief atonic episodes, drop attacks and myoclonic jerks. Patient 2 also displayed absences and behavioral disturbance with episodes of minor status epilepticus. When the patients held both arms outstretched, polygraphic records revealed the spike-and-wave (sp-w) discharges in association with the sudden dropping of an outstretched arm. The drops were due to a loss of tone recorded in deltoid muscles, and coincided with the slow wave components of bilateral sp-w complexes, predominantly on the contralateral side. In the present paper, the clinical and electrophysiologic features of this particular type of seizure are presented in detail. A cortical origin of these episodes is suggested.

Explore related subjects

AnticonvulsantsCerebral CortexChildChild, PreschoolCombined Modality TherapyDominance, CerebralDrug Therapy, CombinationElectroencephalographyEpilepsies, MyoclonicEpilepsies, PartialEpilepsy, AbsenceEvoked PotentialsFemaleFollow-Up StudiesHumansMuscle TonusMusclesNeural InhibitionCase ReportsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

P J Wang, K Omori, H Utsumi, T Izumi, K Yajima, Y Fukuyama. 1984. Partial inhibitory seizures: a report on two cases.. https://doi.org/10.1016/s0387-7604(84)80100-x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.

Medical therapy for essential tremor (ET), a common movement disorder, is often inadequate. We performed a double-blind placebo-controlled randomized trial to evaluate the efficacy and tolerability of zonisamide (ZNS), an antiepileptic agent, in treating ET. Twenty patients (mean age, 60 +/- 15 years) with ET were randomized to receive ZNS or placebo. ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14. Patients were evaluated by accelerometry and the Fahn-Tolosa-Marin (FTM) rating scale at baseline and days 14 and 28, as well as the Clinical Global Impression (CGI-C) scale at day 28. At endpoint, subjects assigned to ZNS were taking a mean dosage of 160 +/- 50 mg/day. There were no significant improvements in the FTM total score or its subsections. Tremor amplitude as assessed by accelerometry significantly improved in the ZNS group compared to the placebo group at endpoint relative to baseline (-0.50 +/- 0.72 vs. 0.30 +/- 0.79 m/s(2); P = 0.03). On the CGI-C, 60% (n = 6) of patients in the ZNS group felt that their tremor was unchanged, while the remaining patients felt that their tremor was "minimally improved." Thirty percent (n = 3) of patients taking ZNS discontinued the study due to side effects (fatigue, headache, paresthesias) while taking 100 mg per day. ZNS did not provide significant improvements in clinical rating scales at study endpoint compared to placebo and was only modestly well tolerated. ZNS was effective in reducing tremor amplitude as measured by accelerometry.

Anticonvulsants↗